Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1976 1
1979 1
1982 2
1983 1
1984 1
1985 1
1986 2
1987 1
1989 1
1991 1
1992 1
1994 1
1995 2
1996 6
1997 7
1998 7
1999 5
2000 6
2001 6
2002 8
2003 11
2004 4
2005 7
2006 5
2007 6
2008 10
2009 10
2010 8
2011 13
2012 15
2013 16
2014 13
2015 16
2016 14
2017 9
2018 8
2019 11
2020 8
2021 12
2022 6
2023 8

Text availability

Article attribute

Article type

Publication date

Search Results

248 results

Results by year

Filters applied: . Clear all
Page 1
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'Cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, Bradley WH, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ; PRIMA/ENGOT-OV26/GOG-3012 Investigators. González-Martín A, et al. Among authors: freyer g. N Engl J Med. 2019 Dec 19;381(25):2391-2402. doi: 10.1056/NEJMoa1910962. Epub 2019 Sep 28. N Engl J Med. 2019. PMID: 31562799 Clinical Trial.
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial.
Falandry C, Rousseau F, Mouret-Reynier MA, Tinquaut F, Lorusso D, Herrstedt J, Savoye AM, Stefani L, Bourbouloux E, Sverdlin R, D'Hondt V, Lortholary A, Brachet PE, Zannetti A, Malaurie E, Venat-Bouvet L, Trédan O, Mourey L, Pujade-Lauraine E, Freyer G; Groupe d’Investigateurs Nationaux pour l’Étude des Cancers de l’Ovaire et du sein (GINECO). Falandry C, et al. Among authors: freyer g. JAMA Oncol. 2021 Jun 1;7(6):853-861. doi: 10.1001/jamaoncol.2021.0696. JAMA Oncol. 2021. PMID: 33885718 Free PMC article. Clinical Trial.
[CHIP and ovarian cancer].
Lécuru F, Bakrin N, Classe JM, Colombo PE, Ferron G, Freyer G, Glehen O, Gouy S, Huchon C, Narducci F, Pocard M, Pomel C, Rouzier R. Lécuru F, et al. Among authors: freyer g. Gynecol Obstet Fertil Senol. 2019 Sep;47(9):617-618. doi: 10.1016/j.gofs.2019.06.007. Epub 2019 Jun 26. Gynecol Obstet Fertil Senol. 2019. PMID: 31252153 French. No abstract available.
Traitement des rechutes tardives du cancer de l’ovaire.
Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B. Floquet A, et al. Among authors: freyer g. Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5. Bull Cancer. 2017. PMID: 28625312 French.
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.
Lauby A, Colomban O, Corbaux P, Peron J, Van Wagensveld L, Gertych W, Bakrin N, Descargues P, Lopez J, Kepenekian V, Glehen O, Philip CA, Devouassoux-Shisheboran M, Tod M, Freyer G, You B. Lauby A, et al. Among authors: freyer g. Cancers (Basel). 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098. Cancers (Basel). 2021. PMID: 35008262 Free PMC article. Review.
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A. de Gramont A, et al. Among authors: freyer g. J Clin Oncol. 2000 Aug;18(16):2938-47. doi: 10.1200/JCO.2000.18.16.2938. J Clin Oncol. 2000. PMID: 10944126 Clinical Trial.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
You B, Robelin P, Tod M, Louvet C, Lotz JP, Abadie-Lacourtoisie S, Fabbro M, Desauw C, Bonichon-Lamichhane N, Kurtz JE, Follana P, Leheurteur M, Piano FD, Ferron G, De Rauglaudre G, Ray-Coquard I, Combe P, Chevalier-Place A, Joly F, Leary A, Pujade-Lauraine E, Freyer G, Colomban O. You B, et al. Among authors: freyer g. Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24. Clin Cancer Res. 2020. PMID: 32209570 Clinical Trial.
[Geriatric oncology: an emergent subspecialty].
Freyer G, Falandry C. Freyer G, et al. Rev Med Interne. 2013 Oct;34(10):589-90. doi: 10.1016/j.revmed.2013.04.002. Epub 2013 May 18. Rev Med Interne. 2013. PMID: 23694957 French. No abstract available.
Pharmacodynamic models for discrete data.
Paule I, Girard P, Freyer G, Tod M. Paule I, et al. Among authors: freyer g. Clin Pharmacokinet. 2012 Dec;51(12):767-86. doi: 10.1007/s40262-012-0014-9. Clin Pharmacokinet. 2012. PMID: 23179578 Review.
Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
Reda M, Macaire P, Bellio H, Uwer L, Ilie S, Lorgis V, Hennequin A, Ladoire S, Rederstorff E, Fumoleau P, Isambert N, Bonnin N, You B, Freyer G, Desmoulins I, Schmitt A. Reda M, et al. Among authors: freyer g. Cancer Chemother Pharmacol. 2022 Feb;89(2):197-208. doi: 10.1007/s00280-021-04395-y. Epub 2022 Jan 8. Cancer Chemother Pharmacol. 2022. PMID: 34997290
248 results